Search

Malignant and normal cells reveal P-glycoprotein-mediated drug efflux, which is governed by phosphorylation. An attenuation in the binding influences the controlling factor in azidopine, revealing the effects of phosphorylation on the working of P-glycoprotein. Transport of drugs and the mediation of P-glycoprotein antagonists in the transport process are influenced by the controlling of the phosphorylation. Verapamil becomes a weak antagonist, as its transport is enhanced due to dephosphorylation.

The effects of sodium butyrate on drug specificity transport of actinomycin D, adriamycin, vinblastine and colchicine were investigated in SW 620 human colon cancer cells. Sodium butyrate was shown to enhance Pgp expression up to 25-fold, but was also noted to inhibit Pgp phosphorylation which affected Pgp transport. Adriamycin, actinomycin D and vinblastine transport were impaired by sodium butyrate as indicated by the increase in intracellular accumulation. Colchine transport remained unaffected as demonstrated by the decreased intracellular accumulation due to increased efflux.

The article explores the epigenetic therapies for cancer, along with mentions that chromatin as one of the earliest identified targets for cancer therapeutics. It describes therapies in development, and delineates challenges in the field of epigenetics. It mentions that epigenetic therapies seek to normalize DNA methylation patterns and post-translational modifications on histones that promote or maintain a malignant phenotype.

Introduction: Transporters comprising the blood-brain barrier complicate delivery of many therapeutics to the central nervous system. The present study ascertained whether the natural product botryllamide G is viable for in vivo inhibition of ABCG2 using lapatinib as a probe for ABCB1 and ABCG2-mediated efflux from the brain. Methods: Wild-type and Mdr1a/Mdr1b (-/-) mice were treated with botryllamide G and lapatinib ("doublet therapy"), and while a separate cohort of wild-type mice was treated with botryllamide, tariquidar and lapatinib ("triplet therapy"). Results: Botryllamide G demonstrates biphasic elimination with a rapid distribution, decreasing below the in vitro IC50 of 6.9 µM within minutes, yet with a relatively slower terminal half-life (4.6 h). In Mdr1a/Mdr1b (-/-) mice, doublet therapy resulted in a significant increase in brain lapatinib AUC at 8 h (2058 h*ng/mL vs 4007 h*ng/mL; P =.031), but not plasma exposure (P =.15). No significant differences were observed after 24 h. Lapatinib brain exposure was greater through 1 h when wild-type mice were administered triplet therapy (298 h*pg/mg vs 120 h*pg/mg; P <.001), but the triplet decreased brain AUC through 24 h vs. mice administered lapatinib alone (2878 h*pg/mg vs 4461hr*ng/mL; P <.001) and did not alter the brain:plasma ratio. Conclusions: In summary, the ABCG2 inhibitor, botryllamide G, increases brain exposure to lapatinib in mice lacking Abcb1, although the combination of botryllamide G and tariquidar increases brain exposure in wild-type mice only briefly (1 h). Additional research is needed to find analogs of this compound that have better pharmacokinetics and pharmacodynamic effects on ABCG2 inhibition. [ABSTRACT FROM AUTHOR]

Venous thromboembolism (VTE) frequently occurs in patients with cancer, and particularly those with pancreatic ductal adenocarcinoma (PDAC). Therapeutic anticoagulation with either low‐molecular‐weight heparin or a direct oral anticoagulant is clearly beneficial in patients who develop a VTE. However, whether thromboprophylaxis improves patient outcomes remains unclear. Studies assessing this risk show a 10%–25% risk of VTE, with reduction to 5%–10% with thromboprophylaxis but no impact on survival. To aid in the risk stratification of patients, several tools have been developed to identify those at highest risk for a VTE event. However, the clinical application of these risk stratification models has been limited, and most patients, even those at the highest risk, will never have a VTE event. New oral anticoagulants have greatly improved the feasibility of prophylaxis but do show increased risk of bleeding in patients with the underlying gastrointestinal dysfunction frequently found in patients with pancreatic cancer. Recently, several completed clinical trials shed new light on this complicated risk versus benefit decision. Here, we present this recent evidence and discuss important considerations for the clinician in determining whether to initiate thromboprophylaxis in patients with PDAC. Implications for Practice: Given the high risk of venous thromboembolism in patients with pancreatic adenocarcinoma (PDAC), whether to initiate prophylactic anticoagulation is a complex clinical decision. This review discusses recent evidence regarding the risk stratification and treatment options for thromboprophylaxis in patients with PDAC, with the goal of providing practicing clinicians with updates on recent developments in the field. This article also highlights important considerations for individualizing the treatment approach for a given patient given the lack of general consensus of uniform recommendations for this patient population. Venous thromboembolism (VTE) frequently occurs in patients with cancer, especially pancreatic ductal adenocarcinoma (PDAC). Several tools have been developed to identify those at highest risk for a VTE event; however, whether thromboprophylaxis improves patient outcomes remains unclear. This article presents evidence and important considerations for the clinician in determining whether to initiate thromboprophylaxis in patients with PDAC. [ABSTRACT FROM AUTHOR]

In a study of 53 psychiatric inpatients (ages 6-13), depressed children reported significantly more hopelessness, more negative self-perceptions, negative self-perceptions across a wider variety of domains, and more dysfunctional attributional styles than nondepressed controls. Additional results suggested that childhood depressive disorders may be heterogeneous with respect to cognitive patterns. (JW)